DrugPatentWatch Database Preview
LAMICTAL XR Drug Profile
» See Plans and Pricing
When do Lamictal Xr patents expire, and when can generic versions of Lamictal Xr launch?
Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has ninety-five patent family members in thirty-eight countries.
The generic ingredient in LAMICTAL XR is lamotrigine. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
US ANDA Litigation and Generic Entry Outlook for Lamictal Xr
A generic version of LAMICTAL XR was approved as lamotrigine by DR REDDYS LABS LTD on January 22nd, 2009.
Summary for LAMICTAL XR
International Patents: | 95 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 126 |
Clinical Trials: | 64 |
Patent Applications: | 2,381 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LAMICTAL XR |
Drug Sales Revenues: | Drug sales revenues for LAMICTAL XR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LAMICTAL XR |
DailyMed Link: | LAMICTAL XR at DailyMed |


See drug prices for LAMICTAL XR

Recent Clinical Trials for LAMICTAL XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pharmtechnology LLC | Phase 1 |
ClinPharmInvest, LLC | Phase 1 |
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Pharmacology for LAMICTAL XR
Drug Class | Mood Stabilizer Anti-epileptic Agent |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Paragraph IV (Patent) Challenges for LAMICTAL XR
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
LAMICTAL XR | TABLET, EXTENDED RELEASE;ORAL | lamotrigine | 022115 | 2014-02-12 |
US Patents and Regulatory Information for LAMICTAL XR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-001 | May 29, 2009 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-004 | May 29, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-002 | May 29, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-005 | Apr 14, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-004 | May 29, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LAMICTAL XR
Country | Patent Number | Estimated Expiration |
---|---|---|
Russian Federation | 2325163 | Start Trial |
China | 1655768 | Start Trial |
Slovenia | 1474114 | Start Trial |
Spain | 2323268 | Start Trial |
Malaysia | 141049 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |